(MENAFN- GlobeNewsWire - Nasdaq) The global Barrett's Esophagus with Dysplasia (BED) market is experiencing significant growth, propelled by the rising prevalence of GERD - a key precursor to BED - and increased awareness of esophageal cancer risks. The adoption of advanced endoscopic technologies like radiofrequency ablation and AI-driven diagnostics is transforming early detection and treatment strategies. With precision medicine and molecular risk stratification becoming integral, the market benefits from improved reimbursement policies and expanding healthcare infrastructure, notably in regions like Asia-Pacific. Despite challenges in screening uptake and cost, BED market dynamics are set to evolve, underpinning better preventive oncology outcomes worldwide.

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Barrett's Esophagus with Dysplasia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets's offering.
The global barrett's esophagus with dysplasia (BED) market is undergoing notable expansion, driven by the increasing prevalence of chronic gastroesophageal reflux disease (GERD) a major precursor to BED alongside rising awareness of esophageal cancer risks and the growing adoption of advanced endoscopic surveillance and therapeutic technologies.
The growth of the BED market is further fuelled by heightened clinical recognition of the condition's progression to high-grade dysplasia and esophageal adenocarcinoma if left untreated. This has spurred the adoption of standardized screening protocols, especially in developed markets such as the U.S., Europe, and Japan. Increasing reliance on technologies such as radiofrequency ablation (RFA), cryoablation, and endoscopic mucosal resection (EMR) is transforming how BED is managed, offering both curative potential and reduced need for invasive surgery. The market is evolving rapidly as healthcare systems and clinicians place greater emphasis on early intervention and individualized patient risk stratification, supported by advanced imaging, AI-assisted diagnostics, and emerging molecular biomarkers.
Key therapeutic and diagnostic segments in the BED market include high-definition endoscopy systems, ablation technologies, biopsy tools, and adjunct molecular diagnostics. Notably, the growing integration of artificial intelligence into surveillance endoscopy, enhancing dysplasia detection rates by reducing operator variability and improving lesion characterization. Moreover, the development of precision medicine approaches such as DNA methylation assays and tissue-based molecular classifiers is enabling risk-based stratification, allowing providers to tailor intervention intensity to patient-specific progression risks.
Improvements in healthcare infrastructure, especially across Asia-Pacific, Latin America, and the Middle East, are expanding access to screening and treatment services. This is complemented by more favourable reimbursement frameworks for endoscopic therapies in high-income countries, which are encouraging earlier and more proactive interventions. Enhanced training programs for gastroenterologists and endoscopic surgeons are also contributing to the diffusion of newer techniques in both urban and regional healthcare settings. As health systems prioritize cancer prevention and outcome-based care, the BED market is becoming a critical node within broader gastroenterology and oncology frameworks.
Advances in digital health tools including AI-enabled diagnostic software, smart biopsy tracking systems, and real-time risk prediction models are reshaping how clinicians diagnose and manage BED. These tools are expected to improve detection accuracy, reduce procedure-related costs, and enable more efficient surveillance strategies. In addition, efforts to personalize BED management based on genetic, behavioural, and phenotypic profiles are gaining traction, enabling more tailored surveillance intervals and targeted therapeutic decisions.
Despite its strong growth trajectory, the BED market faces several challenges. These include limited awareness and screening uptake among at-risk populations, especially in underserved areas; the high cost of endoscopic equipment and ablation devices; and disparities in provider access to advanced training and infrastructure. Patient compliance with long-term surveillance protocols also remains a concern, particularly in asymptomatic individuals. Moreover, regulatory complexity and the slow pace of biomarker validation continue to hinder the commercial rollout of newer diagnostics and therapeutics. Variability in insurance coverage for early-stage interventions further complicates access in several markets.
The competitive landscape of the BED market is characterized by active participation from leading medtech firms, diagnostic developers, and clinical research institutions. Strategic collaborations, acquisitions, and clinical trial partnerships are accelerating the development of integrated diagnostic therapeutic solutions. Increased investment in R&D particularly around non-invasive diagnostics, disposable endoscopic tools, and molecular surveillance platforms is expected to play a pivotal role in shaping the next phase of market evolution.
Looking ahead, the global BED market is well-positioned to sustain its growth, underpinned by rising disease prevalence, clinical innovation, and healthcare system readiness to invest in early intervention strategies. With continued focus on digital innovation, patient-centric care, and biomarker-based personalization, the market is expected to deliver improved long-term outcomes and quality of life for patients at risk of esophageal cancer. As global screening efforts intensify and reimbursement pathways expand, the BED market will increasingly serve as a cornerstone of preventative oncology and precision gastroenterology.
Key Topics Covered:
1. Global Barrett's Esophagus with Dysplasia Market: Industry Analysis
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
1.4 Regulatory Landscape
1.5 Pipeline Analysis
1.6 Market Dynamics
2. Global Barrett's Esophagus with Dysplasia Market (by Region), Value ($Million), 2023-2035
2.1 North America
2.2 Europe
2.3 Asia-Pacific
2.4 Rest-of-the-World
3. Competitive Landscape and Company Profiles
3.1 Competitive Landscape
3.1.1 Mergers and Acquisitions
3.1.2 Partnership, Alliances and Business Expansion
3.1.3 New Offerings
3.1.4 Regulatory Activities
3.1.5 Funding Activities
3.2 Company Profiles

• Abbott Laboratories
• Boston Scientific Corporation
• Cipla Inc.
• Cook Medical
• Eli Lilly and Company
• Johnson & Johnson
• Medtronic plc
• Merck & Co., Inc.
• Olympus Corporation
• Pentax Medical

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN06102025004107003653ID1110154533